Availability of the Q4 memorandum for modeling purposes

Paris, France – January 4th, 2023 – Sanofi announced today that its Q4 2022 memorandum is available for modeling purposes on the Investors page of the company’s website:

https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2022

As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group’s quarterly results. This document contains a reminder of various non-comparable items and exclusivity losses as well as the impact of foreign currency and the number of shares. Sanofi’s fourth quarter 2022 results will be released on February 3, 2023.

About Sanofi
We are an innovative global healthcare company driven by one purpose: we hunt the wonders of science to improve people’s lives. Located in approximately 100 countries, our team is dedicated to transforming the practice of medicine by working to make the impossible possible. We bring potentially life-changing treatments and life-saving immunizations to millions of people around the world, while putting sustainability and social responsibility at the heart of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Gundoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Sally Bain | + 1 617 834 6026 | sally.bain@sanofi.com
Nicholas Obrist | + 33 06 77 21 27 55 | nicolas.obrist@sanofi.com
Victor Rouault | + 33 06 70 93 71 40 | victor.rouault@sanofi.com

Investor Relations
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | eva.schaefer-jansen@sanofi.com
Arnaud Delépine | + 33 06 73 69 36 93 | arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 06 40 56 92 | corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.com
Priya Nanduri | + 1 617 764 6418 | priya.nanduri@sanofi.com

Nathalie Pham | + 33 07 85 93 30 17 | nathalie.pham@sanofi.com

Sanofi Forward-Looking Statements
This press release contains forward-looking…